Perrigo Company plc Restricted Cash, Current
Perrigo Company plc (PRGO) had Restricted Cash, Current of $0 as of 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2025-02-28
- 2024-12-31: Restricted Cash, Current $0.00.
- 2024-09-28: Restricted Cash, Current $1.10M.
- 2024-06-29: Restricted Cash, Current $4.70M.
- 2024-03-30: Restricted Cash, Current $7.00M.
| Period end | Restricted Cash, Current |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-28 |
| 2024-09-28 | $1.10M 10-Q · filed 2024-11-06 |
| 2024-06-29 | $4.70M 10-Q · filed 2024-08-02 |
| 2024-03-30 | $7.00M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $7.00M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |